The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“Departures from the proportional hazards assumption were assessed based on the Schoenfeld residuals [24].”
MethodTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×
“This hypothesis was derived from preclinical data demonstrating that the efficacy of some cancer therapies is related to the creation of a favorable immune microenvironment [5, 8].”
MethodInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“Additional aberrations in the PI3K/AKT, ERK1/2, SRC signaling pathways and loss of PTEN are thought to contribute to resistance but are yet to be validated in the clinical setting [12–14].”
BackgroundBerns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577
Zhang, S., Huang, W.-C., Li, P., Guo, H., Poh, S.-B., Brady, S. W., Xiong, Y., Tseng, L.-M., Li, S.-H., Ding, Z., et al. (2011) · Nature Medicine · doi:10.1038/nm.2309 · Cited by 515
Stagg, J., Loi, S., Divisekera, U., Ngiow, S. F., Duret, H., Yagita, H., Teng, M. W., & Smyth, M. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016569108 · Cited by 496
Cited by
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., Ye, C., Salim, A., Mintoff, C. P., Caramia, F., Salgado, R., Byrne, D. J., Teo, Z. L., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0078-7 · Cited by 992
Self-citationLoi, S., Drubay, D., Adams, S., Pruneri, G., Francis, P. A., Lacroix-Triki, M., Joensuu, H., Dieci, M. V., Badve, S., Demaria, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01010 · Cited by 893
Self-citationClinical relevance of host immunity in breast cancer: from TILs to the clinic
Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890
Self-citationLoi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Self-citationCurrent Landscape of Immunotherapy in Breast Cancer: A Review
Adams, S., Gatti-Mays, M. E., Kalinsky, K., Korde, L. A., Sharon, E., Amiri-Kordestani, L., Bear, H., McArthur, H. L., Frank, E., Perlmutter, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7147 · Cited by 384
Spatial Heterogeneity in the Tumor Microenvironment
Yuan, Y. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026583 · Cited by 342
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262
Self-citationNanosensitizer-mediated augmentation of sonodynamic therapy efficacy and antitumor immunity
Li, Y., Chen, W., Kang, Y., Zhen, X., Zhou, Z., Liu, C., Chen, S., Huang, X., Liu, H.-J., Koo, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42509-7 · Cited by 235
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Sceneay, J., Goreczny, G. J., Wilson, K., Morrow, S., DeCristo, M. J., Ubellacker, J. M., Qin, Y., Laszewski, T., Stover, D. G., Barrera, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1454 · Cited by 156
Prabhakaran, S., Rizk, V. T., Ma, Z., Cheng, C.-H., Berglund, A. E., Coppola, D., Khalil, F., Mulé, J. J., & Soliman, H. H. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0864-z · Cited by 150
Wang, K., Shen, T., Siegal, G. P., & Wei, S. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.09.012 · Cited by 123
Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00728-9 · Cited by 124
Self-citationEffect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
Araujo, J. M., Gomez, A. C., Aguilar, A., Salgado, R., Balko, J. M., Bravo, L., Doimi, F., Bretel, D., Morante, Z., Flores, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23099-7 · Cited by 108
Self-citationProduct review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF
Kearney, C. J., Lalaoui, N., Freeman, A. J., Ramsbottom, K. M., Silke, J., & Oliaro, J. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.94 · Cited by 83
Liu, S., Chen, B., Burugu, S., Leung, S., Gao, D., Virk, S., Kos, Z., Parulekar, W. R., Shepherd, L., Gelmon, K. A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2085 · Cited by 57
Wu, J., Li, X., Teng, X., Rubin, D. L., Napel, S., Daniel, B. L., & Li, R. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1039-2 · Cited by 53
Mittal, D., Caramia, F., Michiels, S., Joensuu, H., Kellokumpu-Lehtinen, P.-L., Sotiriou, C., Loi, S., & Smyth, M. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1567 · Cited by 27
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
Qian, X.-L., Xia, X.-Q., Li, Y.-Q., Jia, Y.-M., Sun, Y.-Y., Song, Y.-M., Xue, H.-Q., Hao, Y.-F., Wang, J., Wang, X.-Z., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36517-2 · Cited by 8
Metadata
- Authors
- Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., Piccart, M. J., Loibl, S., Denkert, C., Smyth, M. J., Joensuu, H., & Sotiriou, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-08
- Volume
- 25
- Issue
- 8
- Pages
- 1544-1550
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2112434826
- Cited by
- 1,256
- References
- 11
- FWCI
- 37.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
